Pharmaceuticals, Biotechnology and Life Sciences
Novartis and Allergan have joined forces to conduct a Phase IIb study to test combination of a Novartis FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).
GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, has initiated a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D).
DermTech, Inc., a player in non-invasive molecular dermatology, has entered into two collaborations with multi-national pharmaceutical companies,
OncoMed Pharmaceuticals Inc said on Monday its experimental lung cancer drug failed a mid-stage study, sending its shares tumbling 30 percent in premarket trading.
Roche has reported interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII.
Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.
When a new drug gets tested, the results of the trials should be published for the rest of the medical world — except much of the time, negative or inconclusive findings go unreported, leaving doctors and researchers in the dark.
Biostar Pharmaceuticals, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, has reported its financial results for the year ended December 31, 2016.
The legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% or reaching more than $24 billion by 2025.
Sensorion, a biotech company specializing in the treatment of inner ear diseases, has appointed Nawal Ouzren as the Company’s new CEO.